Heat Biologics CEO Jeff Wolf talks with Contagion about the firm’s effort to develop a vaccine for the coronavirus focused on combining antibody and T cell immunity.
“We have a very unique vaccine,” Wolf claims, pointing to advantages over existing vaccines.
The gp96 program is being investigated for cancer and has been tested using Department of Defense funding for other infectious diseases.
For part 2 of this interview, see here:
For more coverage of the coronavirus vaccine race, see here:
